InterMune (ITMN +12.4%) soars double-digits following the company's Q2 report. Esbriet revenue rose 162% Y/Y and 37% Q/Q and management hiked the low end of its FY revenue guidance for the drug. Stifel's Stephen Wiley reiterates a Buy recommendation and raises his price target to $18 (from $17) saying Q4 "now likely represents the long-awaited inflection point investors have been waiting to materialize." Nevertheless, Wiley warns pressure could come in the form of Phase 3 data due on Boehringer Ingelheim's nintedanib.